2001 Animal Testing Clinical Development 
Drug Target Review
SEPTEMBER 10, 2024
Drug developer companies across the pharma industry report notable reductions in drug development timelines where 10 to 12 months, from lead monoclonal antibody (mAb) identification to IND application, is the new norm and in which earlier Tox material generation has been a critical component for shortening IND timelines.
Drug Target Review
SEPTEMBER 26, 2023
1-4 This approach saves time, money, and resources, and ultimately leads to safer medicines going forward to the clinic. Another area in need of attention is central nervous system (CNS)-safety testing. The electrophysiological development of cardiomyocytes. 2001 Sep;24(9):517–26. Adv Drug Deliv Rev. Rudy B, McBain CJ.
Expert insights. Personalized for you.
65 
Let's personalize your content